ReviewSerotonin contribution to cardiac valve degeneration: new insights for novel therapies?
Introduction
Heartvalve diseases (HVD) include various disorders that result from the genetic or environmental disruption of leaflet function. These pathologies are divided into two main clinical entities: stenosis, in which pathological leaflet thickening and narrowing inhibit valve opening, and regurgitation or insufficiency, in which the improper coaptation of valve leaflets allows blood backflow. Regardless of the etiology, these valvular pathologies progress slowly and subclinically through molecular and cellular mechanisms, including fibromyxoid or fibrocalcific remodeling (cellular migration, followed by cellular differentiation and extracellular matrix remodeling), which result in symptomatic diseases that require surgical intervention. Of the numerous factors that lead to valvular pathologies (the genetic, inflammatory, and cardiovascular risks that mediate conditions to degenerative pathologies), the contribution of the serotonergic system in these pathologies may be advanced through two clinical contexts: the carcinoid heart and drug-induced valvulopathy. It is surprising to observe that the similar fibromyxoid lesions are induced by benfluorex, a fenfluramine derivative, in both mitral and aortic tissues [1] or in both mitral and tricuspid tissues [2], whereas the valvulogenesis, anatomical and hemodynamic features of each lesion are different. The common macroscopic and histological characteristics shared by drug-induced valvulopathy and acute rheumatic fever make difficult the establishment of the imputability of these drugs in HVD [3] and suggest a similar serotonergic mechanism involved in HVD. The aim of this review is to highlight the contribution of serotonin in HVD. Clinical presentations including carcinoid heart, drug-induced valvulopathy and the degenerative mitral valve disease in the dog, in which serotonin is clearly involved, will be deeply analysed. Cellular and molecular mechanisms will be discussed to underline possible new targets in serotonergic valvulopathies and other kinds of degenerative valve processes.
Section snippets
Serotonin synthesis, metabolism and effectors in cardiac valve tissues
Serotonin (5-hydroxytryptamine or 5-HT) is an endogenous monoamine neurotransmitter /hormone that regulates central (mood, appetite, memory, anxiety, sleep, pain, aggression, and cognition) and peripheral (platelet aggregation, gastro-intestinal motility, cardiac function and blood pressure homeostasis) functions. Over the last decade, several reports emphasized the role of 5-HT in the early phase of wound healing and tissue repair and its major contribution to fibrogenesis. Mechanisms are
Clinical data
The pathogenesis of carcinoid heart disease (CHD) and the development of carcinoid plaques remain incompletely understood; however, an increasing body of evidence points toward 5-HT playing a key role. CHD occurs in more than 50% of patients with carcinoid syndrome associated with neuroendocrine tumors secreting 5-HT. The carcinoid heart is characterized by the development of right-sided valvular dysfunction. The echocardiographic features include the thickening, retraction and regurgitation of
Involvement of mechanical stress to serotonin valve effects
Most of studies are performed on cultured valvular cells but in fact the valve tissue is subjected to considerable mechanical strain. During an average human life span, heart valves open and close approximatively 3 billion times in response to different gradient pressures (more than 200 mmHg). Cardiac valves are living tissues with the ability to repair and remodel in response to damage. Valve biology must be modeled in these extreme hemodynamic conditions. Several laboratories have developed
Discussion
Serotonin and serotonergic 5-HT2 receptors, 5-HT2A and/or 5-HT2B, have been shown to induce the pathological remodeling of cardiac valves (Fig. 2). 5-HT2B receptor stimulation is a common feature of drug-induced valvulopathy. In the field, an important issue is now to identify drugs (old, new or future) at risk for heart valve degeneration. Huang and colleagues screened 2200 compounds that were FDA approved and identified 5-HT2B receptor agonism using calcium-based high-throughput screening [83
Conflicts of interest
None.
Acknowledgements
This study was supported by the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the University Pierre and Marie Curie of Paris, the University of Strasbourg, the Centre Hospitalier et Universitaire de Strasbourg, and by grants from the Fondation de France, the French Ministry of Research, and the Agence Nationale pour la Recherche [ANR-12-BSV1-0015-01].
References (89)
- et al.
Peripheral serotonin synthesis as a new drug target
Trends Pharmacol. Sci.
(2018) - et al.
Therapeutic and adverse actions of serotonin transporter substrates
Pharmacol. Ther.
(2002) - et al.
SLC6 transporters: structure, function, regulation, disease association and therapeutics
Mol. Aspects Med.
(2013) - et al.
Molecular, pharmacological and functional diversity of 5-HT receptors
Pharmacol. Biochem. Behav.
(2002) - et al.
5-hydroxytryptamine (5HT)-Induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in sprague-dawley rats
Exp. Toxicol. Pathol.
(2008) - et al.
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells
Am. J. Pathol.
(2002) - et al.
Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study
Vet. J.
(2015) - et al.
Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data
Cardiovasc. Pathol.
(2013) - et al.
Risk factors for the development and progression of carcinoid heart disease
Am. J. Cardiol.
(2011) - et al.
Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease
J. Am. Coll. Cardiol.
(1998)
A mouse model of carcinoid syndrome and heart disease
J. Surg. Res.
Long-term serotonin effects in the rat are prevented by terguride
Regul. Pept.
Elevated serotonin interacts with Angiotensin-II to result in altered valve interstitial cell contractility and remodeling
Cardiovasc. Eng. Technol.
Drug-induced fibrotic valvular heart disease
Lancet (London, England)
Possible association between 3,4-Methylenedioxymethamphetamine abuse and valvular heart disease
Am. J. Cardiol.
Immunohistochemical characterization of the extracellular matrix in normal mitral valves and in chronic valve disease (Endocardiosis) in dogs
Res. Vet. Sci.
Signaling pathways in mitral valve degeneration
J. Vet. Cardiol., The Mitral Valve
Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans
J. Vet. Cardiol., The Mitral Valve
Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease
Res. Vet. Sci.
Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease
J. Vet. Cardiol.
Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness
Ann. Thorac. Surg.
Elevated cyclic stretch and serotonin result in altered aortic valve remodeling via a mechanosensitive 5-HT(2A) receptor-dependent pathway
Cardiovasc. Pathol.
Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves
J. Vet. Cardiol., The Mitral Valve
5-HT2B antagonism arrests non-canonical TGF-B1-induced valvular myofibroblast differentiation
J. Mol. Cell. Cardiol.
Fenfluramine disrupts the mitral valve interstitial cell response to serotonin
Am. J. Pathol.
Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth Factor-Beta1 via G-protein signal transduction in aortic valve interstitial cells
Am. J. Pathol.
Losartan Inhibits Endothelial-to-Mesenchymal Transformation in Mitral Valve Endothelial Cells by Blocking Transforming Growth Factor-β-Induced Phosphorylation of ERK
Biochem. Biophys. Res. Commun.
Structure and function of serotonin g protein-coupled receptors
Pharmacol. Ther.
Mitral and aortic valvular disease associated with benfluorex use
J. Heart Valve Dis.
Benfluorex-induced severe primary tricuspid and mitral regurgitation requiring a double-valve replacement
Eur. J. Card.-Thor. Surg.
Drug-induced- or rheumatic- valvular heart disease in patients exposed to benfluorex?
PLoS One
Platelet-derived serotonin links vascular disease and tissue fibrosis
J. Exp. Med.
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension
Nat. Med.
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy
Circ. Res.
Serotonergic 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors
Br. J. Pharmacol.
Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease
Nat. Med.
Synthesis of serotonin by a second tryptophan hydroxylase isoform
Science (New York, N.Y.)
Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of Paracrine/Autocrine serotonergic networks
ACS Chem. Neurosci.
International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)
Pharmacol. Rev.
Expression of 5-Hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves
J. Heart Valve Dis.
Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease
Am. J. Vet. Res.
5-hydroxytryptamine (5HT) receptors in the heart valves of Cynomolgus monkeys and sprague-dawley rats
J. Histochem. Cytochem.
Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine
Mol. Pharmacol.
3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
Mol. Pharmacol.
Cited by (22)
Ischemic Mitral Regurgitation and Leaflet Remodeling: Another Arrow Hits the Target
2022, Journal of the American College of CardiologyFenfluramine repurposing from weight loss to epilepsy: What we do and do not know
2021, Pharmacology and TherapeuticsCitation Excerpt :One of these relates to the observation that cardiac valvulopathy is caused by drugs with different pharmacological profiles and chemical structures, such as fenfluramine, benfluorex, pergolide, cabergoline, 3,4-methylenedioxymethamphetamine (MDMA) and methysergide. These drugs or their metabolites share the common ability to bind and stimulate 5-HT2B receptors (Ayme-Dietrich et al., 2019; Fitzgerald et al., 2000; Rothman et al., 2000). In fact, a high affinity for 5-HT2B receptors (i.e., a Ki value close to that of 5-HT or lower) is a reliable predictor of the potential to induce a valvulopathy, whereas drugs with low or moderate affinity for 5-HT2B receptors, such as ropirinole and lorcaserin, have not been associated with the development of valvulopathy (Papoian et al., 2017).
The natural compound andrographolide inhibits human aortic valve interstitial cell calcification via the NF-kappa B/Akt/ERK pathway
2020, Biomedicine and PharmacotherapyCitation Excerpt :Until now, many clinical trials have failed to verify that a pharmaceutical intervention can stop or even slow its progression [4]. Therefore, deep investigation of pharmacological mechanistic-based therapeutic approaches could represent a strategy of condsiderable significance [5]. Andrographolide (AGP) is a natural diterpenoid extracted from the traditional Chinese herbal medicine andrographis paniculate and has been shown to exhibit anti-inflammatory, anti-atherosclerotic, antitumorigenic properties [6].
Cardiovascular safety of psychedelic medicine: current status and future directions
2023, Pharmacological ReportsCarcinoid heart disease in patients with midgut neuroendocrine tumours
2023, Journal of NeuroendocrinologyResearch progress on the role of 5-hydroxytryptamine in cardiovascular diseases
2023, Chinese Journal of Cardiology